Their US growth was earlier guided at 20-25% over the medium term (link), plus they keep on gaining market share in India in all their segments. In the last couple of years, they ran into roadblocks in Africa (specially the institutional business) which seems to be coming back. In essence, it seems that they are well poised for reasonable growth over the next 3 years.
Your question about ANDA pipeline: management plans to file 10-12 ANDAs and launch upto 10 products in the coming year which is what they have also been doing historically.
I am not so sure about this, prices have gone up from 1000 to 1500 since mid-March, plus their price got re-rated sometime last year (around August) when market got clarity about medium term growth prospects.